FDA Approval of VONJO™ (pacritinib)
Breaking News – Another Treatment Option Approved for MPNs CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia Pacritinib a novel JAK2/FLT3 and IRAK inhibitor has been approved for MF patients with low platelets and we hope it will be widely available soon with hopefully…